"Contrary to systemic treatment such as morphine, NTDDS delivers the drug focally, specifically to the nerves experiencing pain which is a major advantage for the wellbeing of the patient," states Darren Wolfe, President of Diamyd Inc., the US subsidiary of Diamyd Medical responsible for the development of NP2 and the NTDDS platform.

David Fink, M.D., Professor and Chairman of the Department of Neurology, University of Michigan, Ann Arbor, Lead Investigator of the Phase I study, is presenting the study today at the Annual Meeting of the Neurological Association in San Francisco.

"I am very pleased with how the study has advanced and excited about the potential to maybe be able to help many patients in the future," says Dr. Fink. "Over 4 million cancer patients in the US experience severe pain, representing a large unmet medical need."

Source : Diamyd Medical